A Prognostic Model to Predict Clinical Outcomes with First-Line Gemcitabine-Based Chemotherapy in Advanced Pancreatic Cancer

Publisher： Karger

E-ISSN： 1423-0232|80|3-4|175-180

ISSN： 0030-2414

Source： Oncology, Vol.80, Iss.3-4, 2011-06, pp. : 175-180

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Inferior Survival of Advanced Pancreatic Cancer Patients Who Received Gemcitabine-Based Chemotherapy but Did Not Participate in Clinical Trials

By  

Oncology, Vol. 81, Iss. 3-4, 2011-10 ,pp. : 143-150

Karger

Access to resources Recommend Favorite

Gemcitabine plus Paclitaxel as First-Line Chemotherapy for Patients with Advanced Breast Cancer

By  

Oncology, Vol. 66, Iss. 1, 2004-03 ,pp. : 18-23

Karger

Access to resources Recommend Favorite

Paclitaxel-Based Chemotherapy for Advanced Pancreatic Cancer after Gemcitabine-Based Therapy Failure: A Case Series of 5 Patients

By  

Case Reports in Oncology, Vol. 4, Iss. 3, 2011-11 ,pp. : 534-541

Karger

Access to resources Recommend Favorite

Clinical Outcome of Paclitaxel and Carboplatin as Second-Line Chemotherapy for Advanced Urothelial Carcinoma Resistant to First-Line Therapy with Gemcitabine and Cisplatin

By  

Urologia Internationalis, Vol. 92, Iss. 2, 2013-11 ,pp. : 180-185

Karger

Access to resources Recommend Favorite

Short Time to Progression under First-Line Chemotherapy Is a Negative Prognostic Factor for Time to Progression and Residual Survival under Second-Line Chemotherapy in Advanced Pancreatic Cancer

By  

Oncology, Vol. 73, Iss. 5-6, 2008-05 ,pp. : 335-339

Karger

Access to resources Recommend Favorite